Committee for Medicinal Products for Human Use (CHMP) has recommended approval of MSD’s KEYTRUDA for two gynaecological ...

Keytruda (pembrolizumab) is an immunotherapy drug used to treat many types of cancer. Your doctor will use imaging, blood tests, and other laboratory tests to monitor whether the drug is working.

Opdivo (nivolumab) and Merck's (NYSE:MRK) Keytruda (pembrolizumab), two highly popular checkpoint inhibitors used in the ...

Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

If a company shows a lot of potential, investors are often willing to pay a premium and take on some risk in exchange for ...

MSD’s cancer immunotherapy, Keytruda, looks set to gain a lucrative first line lung cancer use in Europe, after regulators gave it the green light. Crucially, Keytruda (pembrolizumab ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...

Keytruda has been approved since 2016 as a second ... HNSCC is Bristol-Myers Squibb's Opdivo (nivolumab), which can be used as a second-line option after chemotherapy. BMS' attempts to move ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.

Despite positive KEYNOTE-811 results, Merck & Co’s position in this setting is not devoid of threats from other competitors.